Scarica l'app Stockscreener
38.23
1.30%
-0.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$38.81
Aprire:
$38.92
Volume 24 ore:
2.18M
Relative Volume:
0.53
Capitalizzazione di mercato:
$16.33B
Reddito:
$2.31B
Utile/perdita netta:
$1.66B
Rapporto P/E:
16.64
EPS:
2.297
Flusso di cassa netto:
$827.02M
1 W Prestazione:
-3.59%
1M Prestazione:
-3.25%
6M Prestazione:
+8.61%
1 anno Prestazione:
+51.94%
Intervallo 1D:
$37.98
$38.93
Intervallo di 1 settimana:
$37.88
$39.78
Portata 52W:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.23 | 16.58B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.94 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
740.69 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
878.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.78 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.00 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Hsbc Holdings PLC Sells 77,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Raised by Amundi - MarketBeat
Denali enters into a $275M funding deal with Royalty Pharma - MSN
What Royalty Pharma (RPRX)'s Denali Rare-Disease Royalty Deal and Cash Surge Means For Shareholders - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Royalty Pharma (RPRX): Assessing Valuation After a Strong Multi‑Month Share Price Rally - Sahm
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.
Is It Too Late to Reassess Royalty Pharma After Its 52% Surge in 2025? - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Acquired by Schroder Investment Management Group - MarketBeat
Denali makes $275m funding agreement with Royalty Pharma - Yahoo Finance
Will Royalty Pharma plc (RPD) stock maintain strong growth2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat
Is Royalty Pharma plc stock a good choice for value investors2025 Market Sentiment & Verified Technical Trade Signals - Newser
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - marketscreener.com
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
How Royalty Pharma plc (RPD) stock correlates with oil marketsMarket Activity Summary & Capital Efficiency Focused Strategies - Newser
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics (Nasdaq: DNLI) lands $275M, 9.25% tividenofusp alfa royalty deal - Stock Titan
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser
How Royalty Pharma plc (RPD) stock performs in easing cyclesJuly 2025 Action & Community Consensus Stock Picks - Newser
Arrowstreet Capital Limited Partnership Purchases 1,615,706 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com - Investing.com Nigeria
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.77 million - Investing.com
Transcript : Royalty Pharma plc Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 03 - marketscreener.com
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million - Investing.com
100,000 Shares in Royalty Pharma PLC $RPRX Acquired by Watchtower Advisors LP - MarketBeat
Norges Bank Invests $181.39 Million in Royalty Pharma PLC $RPRX - MarketBeat
Korea Investment CORP Sells 160,900 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by River Road Asset Management LLC - MarketBeat
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Royalty Pharma Plc Azioni (RPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments |
Dec 05 '25 |
Sale |
39.15 |
18,242 |
714,224 |
7,398 |
| Lloyd George W. | EVP, Investments & CLO |
Dec 03 '25 |
Sale |
39.77 |
110,000 |
4,375,008 |
110,000 |
| Coyne Terrance P. | EVP & CFO |
Dec 01 '25 |
Sale |
39.87 |
69,582 |
2,773,956 |
47,260 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.93 |
23,333 |
931,633 |
183,334 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.90 |
18,242 |
727,856 |
25,640 |
1.40%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):